Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Consumer,Bevacizumab,"Glioblastoma multiforme, relapsed or recurrent",Bevacizumab,Recommended for decline,Community and Hospital,Oncology Agents and Immunosuppressants
